SCHEMBL508318

SCHEMBL508318

CCOC(=O)C1(C=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 7/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ATM Q13315 1/20 0.36
OPRD1 P41143 3/20 0.36
OPRK1 P41145 3/20 0.36
ALOX15 P16050 1/20 0.36
SLC22A1 O15245 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
KCNH2 Q12809 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1606644 0.92 SMN1; SMN2 (0.41) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL2553541 0.92 SMN1; SMN2 (0.38) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL2557391 0.90 SMN1; SMN2 (0.37) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL14341367 0.86 ALDH1A1 (0.42) ALDH1A1POLBLMNAHSD17B10SMN1; SMN2
SCHEMBL19381503 0.83 SMN1; SMN2 (0.39) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL2295306 0.83 ALDH1A1 (0.39) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL8241934 0.82 POLB (0.35) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL1119086 0.81 ATM (0.39) ALDH1A1POLBLMNAHSD17B10OPRM1
SCHEMBL31626940 0.80 ATM (0.36) ALDH1A1POLBLMNAOPRM1SMN1; SMN2
Hydrochloric Acid SCHEMBL3834729 0.79 ATM (0.38) ALDH1A1POLBLMNAHSD17B10OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 US disclosed
EP-4536363-A1 SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS Nikang Therapeutics, Inc. (US) 2025-04-16 EP disclosed
CN-119790053-A Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors 霖康疗法公司 2025-04-08 CN disclosed
WO-2025072462-A1 SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
CN-119053595-A Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors 尼坎治疗公司 2024-11-29 CN disclosed
WO-2023240024-A1 SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230295076-A1 ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-09-21 US disclosed
US-11760751-B2 Benzo 2-azaspiro[4.4]nonane compound and use thereof HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) 2023-09-19 US disclosed
WO-2002057264-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO COMPANY LIMITED (JP) 2002-07-25 WO disclosed
EP-1148047-A2 Processes for preparing cyclic compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-10-24 EP disclosed
US-6218548-B1 (TRIARYLMETHYL)AMINOSPIROPYRROLES DAIICHI PAHARMACEUTICAL CO., LTD. (JP) 2001-04-17 US disclosed
US-6013806-A ANTIBACTEIRAL DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-01-11 US disclosed
US-5856518-A Production process of cyclic compound DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-01-05 US disclosed
EP-0829473-A1 PROCESSES FOR PREPARING CYCLIC COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-03-18 EP disclosed
US-5416231-A Prostaglandin I2 derivatives ASAHI GLASS COMPANY, LTD. (JP) 1995-05-16 US disclosed
EP-0553352-B1 NOVEL PROSTAGLANDIN I2 DERIVATIVES ASAHI GLASS CO LTD (JP) 1995-03-15 EP disclosed
EP-0553352-A1 NOVEL PROSTAGLANDIN I2 DERIVATIVES ASAHI GLASS COMPANY LTD. (JP) 1993-08-04 EP disclosed
WO-1992004339-A1 NOVEL PROSTAGLANDIN I2 DERIVATIVES ASAHI GLASS COMPANY LTD. (JP) 1992-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295076-A1 ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF CYP11B2, ALDH7A1, CYP11B1 ALDH1A1 47/4885POLB 1535/4885LMNA 4765/4885
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS CDK2, CCNK, CCNI ALDH1A1 3620/4885POLB 519/4885LMNA 2004/4885
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors CDK2, CCNK, CCNI ALDH1A1 3620/4885POLB 519/4885LMNA 2004/4885
US-11760751-B2 Benzo 2-azaspiro[4.4]nonane compound and use thereof AZI2, GABBR2, CNDP2 ALDH1A1 284/4885POLB 2445/4885LMNA 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.